SCHEMBL5873579

SCHEMBL5873579

c1ccc2cc(-c3cc4cccccc-4c3)cc-2cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
MAOA P21397 1/20 0.50
KMO O15229 1/20 0.48
ALOX5 P09917 1/20 0.48
BACE1 P56817 1/20 0.47
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP1A1 P04798 1/20 0.46
CYP2E1 P05181 1/20 0.46
CYP2C8 P10632 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP4B1 P13584 1/20 0.46
CYP2B6 P20813 1/20 0.46
CYP3A5 P20815 1/20 0.46
CYP2A7 P20853 1/20 0.46
CYP3A7 P24462 1/20 0.46
CYP2F1 P24903 1/20 0.46
CYP2C18 P33260 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5321294 0.96 ALDH1A1 (0.69) ALDH1A1MAOAKMOALOX5CYP1A2
SCHEMBL19618929 0.93 ALDH1A1 (0.64) ALDH1A1MAOAKMOALOX5CYP1A2
SCHEMBL14481975 0.93 ALDH1A1 (0.64) ALDH1A1MAOAKMOALOX5CYP1A2
SCHEMBL8452262 0.92 ALDH1A1 (0.75) ALDH1A1MAOAKMOALOX5BACE1
SCHEMBL4332773 0.92 ALDH1A1 (0.75) ALDH1A1MAOAKMOALOX5BACE1
SCHEMBL481505 0.92 ALDH1A1 (0.75) ALDH1A1MAOAKMOALOX5BACE1
SCHEMBL2401076 0.88 ALDH1A1 (0.69) ALDH1A1MAOAKMOALOX5CYP3A4
SCHEMBL2731883 0.88 ALDH1A1 (0.69) ALDH1A1MAOAKMOALOX5CYP3A4
SCHEMBL5130299 0.88 ALDH1A1 (0.69) ALDH1A1MAOAKMOALOX5CYP1A2
SCHEMBL31734209 0.88 ALDH1A1 (0.69) ALDH1A1MAOAKMOALOX5CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7034174-B2 Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GMBH (DE) 2006-04-25 US disclosed
EP-1318183-B1 Oligomers and Polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GMBH (DE) 2005-05-18 EP disclosed
US-20030122479-A1 Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2003-07-03 US disclosed
EP-1318183-A1 Mono,- oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials MERCK PATENT GmbH (DE) 2003-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030122479-A1 Mono-, oligo- and polymers comprising a 2,6-azulene group and their use as charge transport materials PARN, PARG, SLCO2A1 ALDH1A1 2598/4885MAOA 1048/4885KMO 594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.